Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Alvotech
Deal Size : $10.1 million
Deal Type : Acquisition
Alvotech Acquires Xbrane’s R&D, Strengthening Biosimilars Leadership Globally
Details : Through the acquisition, Alvotech leverages R&D operations and a biosimilar candidate of Xbrane XB003 (certolizumab pegol). It is being evluated for treating crohn disease.
Product Name : XB003
Product Type : Antibody-drug Conjugate
Upfront Cash : $10.1 million
March 20, 2025
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Alvotech
Deal Size : $10.1 million
Deal Type : Acquisition
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Biogen
Deal Size : $88.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzaneâ„¢ and will be the Marketing Authorization Holder.
Product Name : Xcimzane
Product Type : Antibody-drug Conjugate
Upfront Cash : $8.0 million
July 02, 2022
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Biogen
Deal Size : $88.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company has announced the initiation of developing two new biosimilar candidates referencing Keytruda® and Darzalex® respectively. Together with Xdivane™, these new biosimilar candidates form an oncology biosimilar portfolio.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 13, 2021
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xbrane Biopharma Plans to Continue Phase III Trial of its Xlucane® (Ranibizumab) Biosimilar Product
Details : The Xplore trial, which was started in 2019, is intended to study the biosimilarity of Xlucane as compared to Novartis’s Lucentis® in wet age-related macular degeneration (AMD).
Product Name : Xlucane
Product Type : Antibody
Upfront Cash : Inapplicable
April 23, 2020
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable